Valneva SE
VALN · XNASCIK 1836564fmd_01ZCRVGXKCGMXTJJPYGWW6FRAAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 22 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 126 | 110 | 348 | 361 | 154 | 170 | 175 |
| Cost of revenue | 53 | 54 | 188 | 324 | 101 | 99 | 107 |
| Gross profit | 73 | 56 | 160 | 37 | 53 | 71 | 68 |
| Research and development | 38 | 84 | 173 | 105 | 60 | 74 | 85 |
| Selling, general and administrative | 18 | 28 | 48 | – | – | – | – |
| Operating income | (1) | (55) | (61) | (113) | (82) | 13 | (82) |
| Interest expense | 3 | 11 | 17 | 19 | 23 | 24 | 42 |
| Income before taxes | (1) | (65) | (70) | (145) | (99) | (11) | (114) |
| Income tax expense | 1 | (1) | 3 | (2) | 3 | 1 | 1 |
| Net income from continuing operations | (2) | (64) | (73) | (143) | (101) | (12) | (115) |
| Net income | (1) | (55) | (61) | (143) | (101) | (12) | (115) |
| Net income to common shareholders | (2) | (64) | (73) | (143) | (101) | (12) | (115) |